These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 21353142)

  • 21. [Role of hyperammonemia in stuporous states induced by sodium valproate].
    Warter JM; Marescaux C; Rumbach L; Micheletti G; Chabrier G; Koehl C; Imler M; Collard M
    Rev Neurol (Paris); 1983; 139(12):753-7. PubMed ID: 6420866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Valproate-induced hyperammonemia.
    Batshaw ML; Brusilow SW
    Ann Neurol; 1982 Mar; 11(3):319-21. PubMed ID: 6807193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cognitive side effects of valproic acid-induced hyperammonemia in children with epilepsy.
    Nicolai J; Aldenkamp AP; Huizenga JR; Teune LK; Brouwer OF
    J Clin Psychopharmacol; 2007 Apr; 27(2):221-4. PubMed ID: 17414255
    [No Abstract]   [Full Text] [Related]  

  • 24. Valproate-induced hyperammonemic encephalopathy.
    Segura-Bruna N; Rodriguez-Campello A; Puente V; Roquer J
    Acta Neurol Scand; 2006 Jul; 114(1):1-7. PubMed ID: 16774619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adult nonhepatic hyperammonemia: a case report and differential diagnosis.
    LaBuzetta JN; Yao JZ; Bourque DL; Zivin J
    Am J Med; 2010 Oct; 123(10):885-91. PubMed ID: 20920686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Valproic acid-induced encephalopathy in very long course treated patients.
    Rousseau MC; Montana M; Villano P; Catala A; Blaya J; Valkov M; Allouard Y; Bugni E
    Brain Inj; 2009 Nov; 23(12):981-4. PubMed ID: 19831495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reversible Encephalopathy due to Valproic Acid Induced Hyperammonemia in a Patient with Bipolar I Disorder: A Cautionary Report.
    Patel N; Landry KB; Fargason RE; Birur B
    Psychopharmacol Bull; 2017 Jan; 47(1):40-44. PubMed ID: 28138203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Metabolic encephalopathy can be a potentially life-threatening complication from valproic acid].
    Meinardi MC; van den Berg GB; Groenhuijzen A; Driessen JT; Maas HA; Wolfhagen FH
    Ned Tijdschr Geneeskd; 2008 Feb; 152(5):278-82. PubMed ID: 18333544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. On the toxicity of valproic-acid.
    Moreiras Plaza M; Rodríguez Goyanes G; Cuiña L; Alonso R
    Clin Nephrol; 1999 Mar; 51(3):187-9. PubMed ID: 10099893
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors of hyperammonemia in epilepsy patients with valproic acid therapy.
    Kwack DW; Kim DW
    Clin Neurol Neurosurg; 2023 Oct; 233():107962. PubMed ID: 37717359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hyperammonemia following intravenous valproate loading.
    DeWolfe JL; Knowlton RC; Beasley MT; Cofield S; Faught E; Limdi NA
    Epilepsy Res; 2009 Jul; 85(1):65-71. PubMed ID: 19299111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Valproic acid-induced hyperammonemia: a case report.
    McCall M; Bourgeois JA
    J Clin Psychopharmacol; 2004 Oct; 24(5):521-6. PubMed ID: 15349008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factors for valproic acid induced hyperammonemia and its association with cognitive functions.
    Duman B; Can KC; Ağtaş-Ertan E; Erdoğan S; İlhan RS; Doğan Ö; Kumbasar H; Çamsarı UM
    Gen Hosp Psychiatry; 2019; 59():67-72. PubMed ID: 31276904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical alertness to valproic acid-induced hyperammonemia--two case reports.
    Shan JC; Hsieh MH; Liu CC; Wen CC; Liu CM
    J Psychopharmacol; 2010 Jun; 24(6):943-5. PubMed ID: 19304858
    [No Abstract]   [Full Text] [Related]  

  • 35. Valproate-induced hyperammonemic encephalopathy: a brief review.
    Lewis C; Deshpande A; Tesar GE; Dale R
    Curr Med Res Opin; 2012 Jun; 28(6):1039-42. PubMed ID: 22587482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CPS1 T1405N polymorphism, HDL cholesterol, homocysteine and renal function are risk factors of VPA induced hyperammonemia among epilepsy patients.
    Chen L; Tian Q; Zhang M; Chen D; Gao X; Yang H; Li H; Li C; Wen J; Li Y; Tian X; Chen P
    Epilepsy Res; 2019 Aug; 154():139-143. PubMed ID: 31151073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Valproic acid-induced hyperammonemia and thrombocytopenia in an elderly woman.
    Mallet L; Babin S; Morais JA
    Ann Pharmacother; 2004 Oct; 38(10):1643-7. PubMed ID: 15316109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different clinical manifestations of hyperammonemic encephalopathy.
    Gomceli YB; Kutlu G; Cavdar L; Sanivar F; Inan LE
    Epilepsy Behav; 2007 Jun; 10(4):583-7. PubMed ID: 17412645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyperammonemia associated with valproic acid use in elderly psychiatric patients.
    Holroyd S; Overdyke JT
    J Neuropsychiatry Clin Neurosci; 2012; 24(3):372-4. PubMed ID: 23037652
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ammonia induced encephalopathy from valproic acid in a bipolar patient: case report.
    Elgudin L; Hall Y; Schubert D
    Int J Psychiatry Med; 2003; 33(1):91-6. PubMed ID: 12906346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.